APOB and familial hypercholesterolemia: Lipid-lowering drugs with these two molecules as direct targets to complement the unmet need of familial hypercholesterolemia patients by conventional therapies include the small-molecule inhibitor of MTP, Lomitapide6, and the antisense oligonucleotide of APOB, Mipomersen7.